# OnCo record imid (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/imid/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "imid" ;
  schema:name "Immunomodulatory drugs (IMiDs) and CELMoDs"@en ;
  schema:alternateName "IMiD"@en, "IMiDs"@en, "immunomodulatory drugs"@en, "immunomodulatory agents"@en, "immunomodulatory imide drugs"@en, "CELMoD"@en, "CELMoDs"@en, "cereblon modulators"@en, "cereblon E3 ligase modulators"@en, "IKZF1/3 degradation"@en, "cereblon modulator"@en, "immunomodulatory drug"@en ;
  schema:description "Thalidomide and its descendants lenalidomide and pomalidomide, which hijack a cellular waste-disposal tag (cereblon) to destroy two proteins myeloma cells depend on, while also revving up T and NK cells. CELMoDs such as iberdomide and mezigdomide bind cereblon more tightly and work after lenalidomide fails; clots, low blood counts and birth defects are class risks."@en ;
  schema:url <https://onco.cc/terms/imid/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Immunomodulatory_imide_drug> ;
  schema:citation <https://en.wikipedia.org/wiki/Immunomodulatory_imide_drug> ;
  onco:related <https://onco.cc/terms/vrd/>, <https://onco.cc/terms/proteasome-inhibitor/>, <https://onco.cc/terms/vte/>, <https://onco.cc/cancers/mds/> ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/molecular-glue-platforms/>, <https://onco.cc/technologies/protac-degrader/> ;
  onco:drugs <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/pomalidomide/>, <https://onco.cc/drugs/thalidomide/> .